Devicor Medical Products Inc. has signed exclusive rights to market a new beta-glucan tissue marker used in breast biopsies.
The company bought the rights from Carbon Medical Technologies. Devicor is owned by Mammotome, a worldwide leader of biopsy site markers and vacuum-assisted biopsy devices, according to a company press release.
"Doctors have told us that consistent and long-lasting visibility under ultrasound and other imaging modalities is important for the treatment of their patients. We believe this product provides that solution," stated Tom Daulton, CEO of Devicor and Mammotome, in the release.